Clinical Study
Effects of Oral L-Carnitine on Liver Functions after Transarterial Chemoembolization in Intermediate-Stage HCC Patients
Table 1
Baseline clinical and laboratory data.
| | Parameter (mean ± SD) | L-carnitine group () | Control group () | |
| | Sex (male/female) | 17/7 | 21/5 | 0.5 | | Age | 71.6 ± 7.6 | 72.3 ± 6.8 | 0.7 | | CP score | 6.04 ± 1.04 | 5.88 ± 0.99 | 0.4 | | Stage (2/3/4) | 7/15/2 | 9/15/2 | 0.9 | | Drug (cisplatin/others) | 18/6 | 21/5 | 0.3 | | BCAA (yes/no) | 16/8 | 12/14 | 0.1 | | S. albumin (g/dL) | 3.22 ± 0.57 | 3.35 ± 0.56 | 0.2 | | PT (%) | 86.7 ± 19.4 | 89.2 ± 17 | 0.5 | | T. bilirubin (mg/dL) | 1.02 ± 0.57 | 0.93 ± 0.46 | 0.4 | | ALT (U/L) | 32.6 ± 17.6 | 41.8 ± 28.8 | 0.3 | | AST (U/L) | 51.5 ± 25.9 | 57 ± 37.8 | 0.7 | | GGTP (U/L) | 70.7 ± 80.9 | 66.3 ± 67.3 | 0.8 | | Ascites (no/moderate/massive) | 21/3/0 | 21/5/0 | 0.2 | | Encephalopathy (yes/no) | 24/0 | 26/0 | 0.6 |
|
|
SD: standard deviation; CP: Child-Pugh; BCAA: branched-chain amino acids; S. albumin: serum albumin; PT: prothrombin time; T. bilirubin: total bilirubin; ALT: alanine aminotransferase; AST: aspartate aminotransferase; GGTP: gamma-glutamyl transpeptidase.
|
